Newsroom

BEIJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to th...

中国北京--(BUSINESS WIRE)--(美国商业资讯)-- 百奥赛图（北京）医药科技股份有限公司（以下简称“百奥赛图”，SSE: 688796；HKEX: 02315），一家以创新技术驱动新药研发的国际性生物技术公司，今日宣布，合作伙伴IDEAYA Biosciences, Inc. (Nasdaq: IDYA) 已在一款在研的B7H3/PTK7双特异性TOP1 ADC IDE034 I 期剂量递增/扩展临床试验中完成首例患者给药。根据双方此前签订的选择权及许可协议，首例患者给药将触发IDEAYA向百奥赛图支付500万美元里程碑款。 据IDEAYA介绍，该I期研究旨在评估IDE034作为单药治疗的安全性、耐受性及药代动力学（PK）。随着项目推进，IDEAYA 亦计划探索 IDE034 与 DNA 损伤反应（DDR）相关药物的联合治疗方案，包括其自主研发的口服 PARG 抑制剂 IDE161。IDE034是一款潜在同类首创的B7H3/PTK7双特异性TOP1 ADC，由百奥赛图自主开发，并于2024年7月授权给IDEAYA。IDEAYA表示，IDE034设计的差异化在于当B7H3...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the compa...

CAMDEN, Ark.--(BUSINESS WIRE)--Secretary of War Pete Hegseth visited the L3Harris Technologies (NYSE: LHX) Camden site today as part of his nationwide “Arsenal of Freedom” tour, highlighting the importance of American manufacturing capacity in strengthening the defense industrial base and supporting U.S. and allied warfighters. Secretary Hegseth toured several of the site’s solid rocket motor production facilities and spoke with the 1,500 employees who design, build and deliver propulsion syste...

PHILADELPHIA--(BUSINESS WIRE)--In recognition of National Condom Month, sex and relationship therapist Dr. Deb Laino is encouraging young adults to prioritize safer sex practices - not just for protection, but for the emotional and relational benefits that come with feeling secure and aligned with your partner. As conversations around consent and sexual wellness continue to evolve, Dr. Laino emphasizes that condoms are not just about prevention - they help create a shared understanding of respo...

TAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group (“Baldwin” or the “Company”) (NASDAQ: BWIN), a leading independent insurance brokerage and advisory firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced a long-planned leadership transition within its Underwriting, Capacity, & Technology Solutions (“UCTS”) operating group, effective January 1, 2027. Amy Carlisle will become Chief Executive Officer of UCTS, succeeding Jim Roche, who wi...

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Paysafe Limited (“Paysafe” or the “Company”) (NYSE:PSFE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 7, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Franklin BSP Realty Trust, Inc. (“Franklin” or the “Company”) (NYSE:FBRT) securities during the period of November 5, 2024 through February 22, 2026, inclusive (“the Class Period”). If you suffered a loss on your Franklin investments, you have until April 27, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff appli...

CHICAGO--(BUSINESS WIRE)--Equity Residential (NYSE: EQR) today announced that members of the Company’s senior management team, including the Company’s President and CEO, Mark J. Parrell, will participate in a roundtable presentation at the Citi 2026 Global Property CEO Conference on Tuesday, March 3, 2026 at 11:00 a.m. ET. The event will be web cast live. A link to the web cast will be available in the Presentations section of the Investor section of the Company’s website at www.equityapartment...

北卡羅來納州羅利--(BUSINESS WIRE)--(美國商業資訊)-- Caidya是一家全球首屈一指的中型委託研究機構(CRO)，專注為創新生物製藥企業加快臨床研發進程。公司今日宣布任命Michael Clay為營運長(COO)。Clay將負責Caidya的全球營運交付、客戶合作模式和執行策略，進一步強化公司為美國、歐洲和亞太地區創新生物製藥試驗委託者提供服務的能力。 Clay在全球專案交付和研究中心合作策略方面擁有卓越的過往業績。他曾領導遍及60多個國家的大型全球計畫，打造了以營運嚴謹性和贏得試驗委託者信任而著稱的高績效交付團隊。 值得一提的是，Clay在亞太地區擁有豐富的領導經驗——在該地區，速度、監管細則和與研究中心的密切合作對成功至關重要。他親自參與研究中心合作和區域執行的方式，與Caidya獨特的全球布局和在中國的強大影響力高度契合——中國對於創新生物科技研發和病患可及性而言正日益成為至關重要的地區。 Clay最近擔任Fortrea全球專案交付資深副總裁，負責超過500項全球臨床試驗。其職業生涯中還曾在其他全球委託研究機構和研究中心管理機構擔任營運長和高階營運職務。他在...